Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2000Blood

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlan ColowickThreshold Pharmaceuticals (United States)RBRhonda L. BohnCorban University
Jerry Avorn
Jerry AvornBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Colowick et al. (2000) studied this question.

synapsesocial.com/papers/6a6fe309b27f158178271e00https://doi.org/10.1182/blood.v96.5.1698.h8001698_1698_1702
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIII1981 · 310 citations
  2. 2Clinical experience with recombinant factor VIIa1998 · 221 citations
  3. 3A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A1997 · 47 citations
  4. 4A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.1994 · 353 citations
  5. 5Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B1992 · 974 citations